Clinical trials
Dyslipidemias trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2003 | 1 |
| 2005 | 3 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 3 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 5 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 6 |
| 2024 | 2 |
| 2025 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 31 |
| Unknown status | 5 |
| Terminated | 3 |
| Recruiting | 3 |
| Active, not recruiting | 3 |
| Not yet recruiting | 2 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Pavia | 5 |
| Amgen | 4 |
| Sanofi | 4 |
| Kowa Research Europe | 3 |
| Novartis Pharmaceuticals | 3 |
| Iperboreal Pharma Srl | 2 |
| Takeda | 2 |
| Tanabe Pharma Corporation | 2 |
| University of Padova | 2 |
| 89bio, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dyslipidemias | 49 |
| Hypercholesterolemia | 11 |
| Obesity | 9 |
| Diabetes Mellitus, Type 2 | 8 |
| Hyperlipidemias | 6 |
| Cardiovascular Diseases | 5 |
| Hypertension | 5 |
| Atherosclerosis | 4 |
| Diabetes Mellitus | 4 |
| Hypertriglyceridemia | 3 |
Trials
Showing 51 to 49 of 49. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.